Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
NCT07136012Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Aug 2025
- Primary completion
- Oct 2031
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
A Phase 3 trial of olpasiran in cardiovascular disease (CVD), sponsored by Amgen. Started Aug 2025; status: recruiting.
02
Drugs
olpasiran
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07136012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136012.